Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors
To access this article, please choose from the options below
PII: S0090-3019(07)00920-2
doi:10.1016/j.surneu.2007.07.066
© 2008 Elsevier Inc. All rights reserved.
Refers to erratum:
- Erratum
